Clinical Experience with Treatments of Gastric Neuroendocrine Neoplasms

Abstract

In this study, we aimed to clarify the clinical features of gastric neuroendocrine neoplasms (NENs).

We retrospectively analyzed clinicopathological parameters and clinical outcomes of a total of 12 patients treated with the diagnosis of gastric NEN in Hokkaido University Hospital from November 2016 to April 2020.

Of the 12 patients with gastric NEN, ten had neuroendocrine tumor (NET) and two had neuroendocrine cancer (NEC). Of 10 NET patients, six had Rindi type I, two had Rindi type II, and two had Rindi type III. There were eight hypergastrinemia patients. As to treatments selected by the Rindi classification, type I patients underwent total gastrectomy (n=1), distal gastrectomy (n=1), partial resection (n=2), endoscopic dissection (n=1) and observation (n=1), and all six have been alive with no recurrence. One type II patient has been kept in observation for other diseases, and another one is undergoing a somatostain analog for unresectable liver metastases. The both type III patients underwent partial resection and proximal gastrectomy with no recurrence. One NEC patient died for sepsis and another one selected palliative therapy. In conclusion, we should decide the treatment of gastric NENs, which manifest in a variety of pathologic conditions, according to the Rindi classification.